Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future
Open Access
- 2 May 2024
- journal article
- review article
- Published by MDPI AG in Veterinary Sciences
- Vol. 11 (5) , 199
Abstract
Molecular biomarkers are central to personalised medicine for human cancer patients. It is gaining traction as part of standard veterinary clinical practice for dogs and cats with cancer. Molecular biomarkers can be somatic or germline genomic alterations and can be ascertained from tissues or body fluids using various techniques. This review discusses how these genomic alterations can be determined and the findings used in clinical settings as diagnostic, prognostic, predictive, and screening biomarkers. We showcase the somatic and germline genomic alterations currently available to date for testing dogs and cats in a clinical setting, discussing their utility in each biomarker class. We also look at some emerging molecular biomarkers that are promising for clinical use. Finally, we discuss the hurdles that need to be overcome in going ‘bench to bedside’, i.e., the translation from discovery of genomic alterations to adoption by veterinary clinicians. As we understand more of the genomics underlying canine and feline tumours, molecular biomarkers will undoubtedly become a mainstay in delivering precision veterinary care to dogs and cats with cancer.Keywords
Funding Information
- Winn Feline Foundation (EC22-021)
- CVS (UK) Ltd. (EC22-021)
- Kennel Club Charitable Trust (KCCT) (EC22-021)
This publication has 257 references indexed in Scilit:
- Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)Annals of Oncology, 2022
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patientsGenes, Chromosomes and Cancer, 2021
- Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translationAdvanced Drug Delivery Reviews, 2021
- Independent real‐world application of a clinical‐grade automated prostate cancer detection systemThe Journal of Pathology, 2021
- Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatmentVeterinary Medicine and Science, 2019
- Canine urothelial carcinoma: genomically aberrant and comparatively relevantChromosome Research, 2015
- Genetic variations of BRCA1 and BRCA2 genes in dogs with mammary tumoursVeterinary Research Communications, 2013
- Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsBreast Cancer Research and Treatment, 2009
- On the nature of susceptibility to cancer. The presidential addressCancer, 1980